Portal de Periódicos da CAPES

Care for patients with rheumatic diseases during COVID‐19 pandemic: A position statement from APLAR

2020; Wiley; Volume: 23; Issue: 6 Linguagem: Inglês

10.1111/1756-185x.13863

1756-185X

Lai‐Shan Tam, Yoshiya Tanaka, Rohini Handa, Chi‐Chen Chang, Yew Kuang Cheng, Nazrul Isalm, Mengtao Li, Jose Paulo Lorenzo, Yeong Wook Song, Kazuhiko Yamamoto, Xiaofeng Zeng, Syed Atiqul Haq,

Long-Term Effects of COVID-19

International Journal of Rheumatic DiseasesVolume 23, Issue 6 p. 717-722 EXPERT COMMENTS Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR Lai-Shan Tam, Lai-Shan Tam orcid.org/0000-0001-6410-8852 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, ChinaSearch for more papers by this authorYoshiya Tanaka, Yoshiya Tanaka orcid.org/0000-0002-0807-7139 The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanSearch for more papers by this authorRohini Handa, Rohini Handa orcid.org/0000-0001-6685-4170 Apollo Indraprastha Hospitals, New Delhi, IndiaSearch for more papers by this authorChi-Chen Chang, Chi-Chen Chang Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, TaiwanSearch for more papers by this authorYew Kuang Cheng, Yew Kuang Cheng Allergy, Arthritis & Rheumatism Clinic, Farrer Park Hospital, Singapore City, Singapore Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, SingaporeSearch for more papers by this authorNazrul Isalm, Nazrul Isalm Deptartment of Rheumatology, BSMMU, Dhaka, BangladeshSearch for more papers by this authorMengtao Li, Mengtao Li Department of Rheumatology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College & Chinese Academy of Medical Science, Peking Union Medical College Hospital, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, ChinaSearch for more papers by this authorJose Paulo Lorenzo, Jose Paulo Lorenzo Makati Medical Center, Makati, PhilippinesSearch for more papers by this authorYeong-Wook Song, Yeong-Wook Song orcid.org/0000-0002-5384-3437 Department of Internal Medicine, Seoul National University Hospital, Seoul, South KoreaSearch for more papers by this authorKazuhiko Yamamoto, Kazuhiko Yamamoto Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, JapanSearch for more papers by this authorXiaofeng Zeng, Xiaofeng Zeng Department of Rheumatology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College & Chinese Academy of Medical Science, Peking Union Medical College Hospital, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, ChinaSearch for more papers by this authorSyed Atiqul Haq, Corresponding Author Syed Atiqul Haq [email protected] orcid.org/0000-0003-4154-7283 BSM Medical University, Dhaka, Bangladesh Correspondence Syed Atiqul Haq, BSM Medical University, Dhaka, Bangladesh. Email: [email protected]Search for more papers by this author Lai-Shan Tam, Lai-Shan Tam orcid.org/0000-0001-6410-8852 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, ChinaSearch for more papers by this authorYoshiya Tanaka, Yoshiya Tanaka orcid.org/0000-0002-0807-7139 The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, JapanSearch for more papers by this authorRohini Handa, Rohini Handa orcid.org/0000-0001-6685-4170 Apollo Indraprastha Hospitals, New Delhi, IndiaSearch for more papers by this authorChi-Chen Chang, Chi-Chen Chang Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, TaiwanSearch for more papers by this authorYew Kuang Cheng, Yew Kuang Cheng Allergy, Arthritis & Rheumatism Clinic, Farrer Park Hospital, Singapore City, Singapore Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, SingaporeSearch for more papers by this authorNazrul Isalm, Nazrul Isalm Deptartment of Rheumatology, BSMMU, Dhaka, BangladeshSearch for more papers by this authorMengtao Li, Mengtao Li Department of Rheumatology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College & Chinese Academy of Medical Science, Peking Union Medical College Hospital, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, ChinaSearch for more papers by this authorJose Paulo Lorenzo, Jose Paulo Lorenzo Makati Medical Center, Makati, PhilippinesSearch for more papers by this authorYeong-Wook Song, Yeong-Wook Song orcid.org/0000-0002-5384-3437 Department of Internal Medicine, Seoul National University Hospital, Seoul, South KoreaSearch for more papers by this authorKazuhiko Yamamoto, Kazuhiko Yamamoto Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, JapanSearch for more papers by this authorXiaofeng Zeng, Xiaofeng Zeng Department of Rheumatology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College & Chinese Academy of Medical Science, Peking Union Medical College Hospital, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Beijing, ChinaSearch for more papers by this authorSyed Atiqul Haq, Corresponding Author Syed Atiqul Haq [email protected] orcid.org/0000-0003-4154-7283 BSM Medical University, Dhaka, Bangladesh Correspondence Syed Atiqul Haq, BSM Medical University, Dhaka, Bangladesh. Email: [email protected]Search for more papers by this author First published: 27 May 2020 https://doi.org/10.1111/1756-185X.13863Citations: 19Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD open. 2019; 5(2):e001041. 10.1136/rmdopen-2019-001041 PubMedWeb of Science®Google Scholar 2Lewnard JA, Lo NC. Scientific and ethical basis for social-distancing interventions against COVID-19. Lancet Infect Dis. 2020.https://doi.org/10.1016/S1473-3099(20)30190-0 10.1016/S1473-3099(20)30190-0 PubMedWeb of Science®Google Scholar 3Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID- 19: a systematic review and meta-analysis. Arch Acad Emerg Med. 2020; 8(1): e35. PubMedGoogle Scholar 4Higham A, Bostock D, Booth G, Dungwa JV, Singh D. The effect of electronic cigarette and tobacco smoke exposure on COPD bronchial epithelial cell inflammatory responses. Int J Chron Obstruct Pulmon Dis. 2018; 13: 989-1000. 10.2147/COPD.S157728 CASPubMedWeb of Science®Google Scholar 5Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). J Clin Med. 2020; 9(3): 841. 10.3390/jcm9030841 CASPubMedWeb of Science®Google Scholar 6Zhi K, Wang L, Han Y, et al. Trends in cigarette smoking among older male adults in China: an urban-rural comparison. J Appl Gerontol. 2019; 38(6): 884-901. 10.1177/0733464817716967 PubMedWeb of Science®Google Scholar 7Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014; 73(1): 62-68. 10.1136/annrheumdis-2013-204223 PubMedWeb of Science®Google Scholar 8Wen Y-C, Hsiao F-Y, Lin Z-F, Fang C-C, Shen L-J. Risk of stroke associated with use of nonsteroidal anti-inflammatory drugs during acute respiratory infection episode. Pharmacoepidemiol Drug Saf. 2018; 27(6): 645-651. 10.1002/pds.4428 CASPubMedWeb of Science®Google Scholar 9Wen Y-C, Hsiao F-Y, Chan KA, Lin Z-F, Shen L-J, Fang C-C. Acute respiratory infection and use of nonsteroidal anti-inflammatory drugs on risk of acute myocardial infarction: a nationwide case-crossover study. J Infect Dis. 2017; 215(4): 503-509. 10.1093/infdis/jiw603 PubMedWeb of Science®Google Scholar 10Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017; 18(1): 256. 10.1186/s12882-017-0673-8 PubMedWeb of Science®Google Scholar 11Voiriot G, Philippot Q, Elabbadi A, Elbim C, Chalumeau M, Fartoukh M. Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients. J Clin Med. 2019; 8(6): 786. 10.3390/jcm8060786 CASPubMedWeb of Science®Google Scholar 12Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020; 368: m1185. 10.1136/bmj.m1185 PubMedGoogle Scholar 13Lai C-C, Liu YH, Wang C-Y, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2): facts and myths. J Microbiol Immunol Infect. 2020.https://doi.org/10.1016/j.jmii.2020.02.012 10.1016/j.jmii.2020.02.012 Google Scholar 14Mihai C, Dobrota R, Schröder M, et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis. 2020; 79(5): 668-669. 10.1136/annrheumdis-2020-217442 CASPubMedWeb of Science®Google Scholar 15Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020; 79(5): 667-668. 10.1136/annrheumdis-2020-217424 CASPubMedWeb of Science®Google Scholar 16Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. 2020; 2020–217615.https://doi.org/10.1136/annrheumdis-2020-217615 Google Scholar 17Guilpain P, Le Bihan C, Foulongne V, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of COVID- 19: lessons from a case with severe pneumonia. Ann Rheum Dis. 2020; 19: 2020-217549. Google Scholar 18Favalli EG, Agape E, Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol. 2020; 200507.https://doi.org/10.3899/jrheum.200507 10.3899/jrheum.200507 Web of Science®Google Scholar 19Gianfrancesco MA, Hyrich KL, Gossec L, et al. Rheumatic disease and COVID- 19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020; 30095-30103.https://doi.org/10.1016/S2665-9913(20)30095-3 Google Scholar 20McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020; 19(6):e102537. 10.1016/j.autrev.2020.102537 CASPubMedWeb of Science®Google Scholar 21Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-1069. 10.1001/jama.2020.1585 CASPubMedWeb of Science®Google Scholar 22Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395(10223): 473-475. 10.1016/S0140-6736(20)30317-2 CASPubMedWeb of Science®Google Scholar 23Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery. 2020; 6(1): 16. 10.1038/s41421-020-0156-0 CASPubMedWeb of Science®Google Scholar 24Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-271. 10.1038/s41422-020-0282-0 CASPubMedWeb of Science®Google Scholar 25Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 105949.https://doi.org/10.1016/j.ijantimicag.2020.105949 10.1016/j.ijantimicag.2020.105949 PubMedWeb of Science®Google Scholar 26Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020; 49(1): 215-219. Google Scholar 27Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Méd Mal Infect. 2020; 50(4): 384. 10.1016/j.medmal.2020.03.006 CASPubMedWeb of Science®Google Scholar 28Mathian A, Mahevas M, Rohmer J, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020;e217566.https://doi.org/10.1136/annrheumdis-2020-217566 Web of Science®Google Scholar 29Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Investig. 2020; 30(5): 2620-2629. 10.1172/JCI137244 Web of Science®Google Scholar 30Chen H, Wang F, Zhang P, et al. Management of cytokine release syndrome related to CAR-T cell therapy. Front Med. 2019; 13(5): 610-617. 10.1007/s11684-019-0714-8 PubMedWeb of Science®Google Scholar 31Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020; 117(20): 10970-10975.https://doi.org/10.1073/pnas.2005615117 10.1073/pnas.2005615117 CASPubMedWeb of Science®Google Scholar 32Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395(10223): e30-e31. 10.1016/S0140-6736(20)30304-4 CASPubMedWeb of Science®Google Scholar 33Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020.https://doi.org/10.1016/S1473-3099(20)30262-0 10.1016/S1473-3099(20)30262-0 PubMedWeb of Science®Google Scholar Citing Literature Volume23, Issue6June 2020Pages 717-722 ReferencesRelatedInformation